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Abstract
Background: Our group previously demonstrated that a DNA plasmid encoding the
mycobacterial 65-kDa heat shock protein (DNA-HSP65) displayed prophylactic and therapeutic
effect in a mice model for tuberculosis. This protection was attributed to induction of a strong
cellular immunity against HSP65. As specific immunity to HSP60 family has been detected in
arthritis, multiple sclerosis and diabetes, the vaccination procedure with DNA-HSP65 could induce
a cross-reactive immune response that could trigger or worsen these autoimmune diseases.
Methods: In this investigation was evaluated the effect of a previous vaccination with DNA-HSP65
on diabetes development induced by Streptozotocin (STZ). C57BL/6 mice received three vaccine
doses or the corresponding empty vector and were then injected with multiple low doses of STZ.
Results: DNA-HSP65 vaccination protected mice from STZ induced insulitis and this was
associated with higher production of IL-10 in spleen and also in the islets. This protective effect was
also concomitant with the appearance of a regulatory cell population in the spleen and a decreased
infiltration of the islets by T CD8+ lymphocytes. The vector (DNAv) also determined
immunomodulation but its protective effect against insulitis was very discrete.
Conclusion: The data presented in this study encourages a further investigation in the regulatory
potential of the DNA-HSP65 construct. Our findings have important implications for the
development of new immune therapy strategies to combat autoimmune diseases.
Background
Type 1 diabetes is an autoimmune disorder characterized
by destruction of the insulin-producing β cells found in
the pancreatic islets of Langerhans [1,2]. This condition
manifests as a chronic inflammatory response involving
islet infiltration (insulitis) by lymphocytes and mono-
cytes. In susceptible strains of mice, an inflammatory
form of diabetes with clinical and immunohistological
features similar to those of human type 1 diabetes melli-
tus can be induced by injections with multiple low doses
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of streptozotocin (STZ) [3,4]. The majority of these mice
develop hyperglycemia within 2-3 weeks after STZ injec-
tions [3,4].
The primary mediators of β-cell destruction are CD4+ and
CD8+ T cells [5,6]. Pathogenic CD4+ T cells typically
exhibit a T-helper (Th)-1 cell phenotype, characterized by
increased secretion of interferon gamma (IFN-γ) and
tumor necrosis factor alpha (TNF-α). In addition, a
number of β cell autoantigens, including insulin, islet
antigen 2, and glutamic acid decarboxylase 65 (GAD65)
have been identified as targets of CD4+ Th1 cells [7]. Fur-
thermore, Cohen et al., showed that, early in the process
of β-cell destruction, nonobese diabetic (NOD) mice
spontaneously developed antibodies and T cells reactive
to murine 60-kDa heat shock protein (Hsp60) [8,9],
which is cross-reactive with the mycobacterial Hsp65 mol-
ecule [10].
Interestingly, administration of β cell auto-antigens or
derived peptides can prevent initiation of the disease
process or even suppress established β cell autoimmunity
under certain conditions in mice [11-16]. In many of
these studies, protection is mediated through the induc-
tion of β cell-specific regulatory T cells. Th2 and/or Th3
cells suppress Th1 cell differentiation through a bystander
mechanism involving secretion of regulatory cytokines
including interleukin (IL)-4, IL-10, and transforming
growth factor beta (TGF-β) [17,18]. These cytokines either
act directly on naive T cells or modulate the function of
antigen-presenting cells.
A great deal of interest has been focused on the use of plas-
mid DNA to elicit cellular and humoral immunity in the
context of infectious diseases and cancer immunotherapy
[19,20]. Combinations of plasmid DNAs encoding anti-
gens and different cytokines can be used to influence the
nature and magnitude of the immune response. They are
used, for example, to prevent autoimmunity in various
models [21-23]. Cohen et al., showed that vaccination
with a DNA construct encoding human Hsp60 inhibited
diabetes in NOD mice. Prevention of diabetes was associ-
ated with decreased insulitis, and down-regulation of the
proliferative T-cell response to Hsp60 [24].
Our group has explored the prophylactic and therapeutic
potential of a DNA vaccine containing the gene of a heat
shock protein from Mycobacterium leprae (DNA-HSP65) in
experimental tuberculosis [25-28]. We also observed that
this vaccine was protective against experimental pristane-
induced arthritis [29] and spontaneous diabetes in non-
obese diabetic mice [30]. In the arthritis model this effect
was associated with down-regulation in IL-6 and IL-12
production and up-regulation of the anti-inflammatory
cytokine IL-10 [29]. Moreover, the protection in NOD
mice was associated with a clear shift in the cellular infil-
tration pattern in the pancreas and an increased staining
for IL-10 in the islets [30].
Within this context, the present study was designed to
investigate the ability of the DNA-HSP65 vaccine to mod-
ulate the development of STZ-induced diabetes in C57BL/
6 mice. In addition, we investigated the mechanisms asso-
ciated with the immune modulation that DNA-HSP65
injection elicited in the spleen and pancreas. Our results
show that either the vector (DNAv) alone or DNA carrying
the gene encoding Hsp65 had no deleterious effect on the
course of STZ-induced diabetes. In addition, the adminis-
tration of DNA-HSP65 prior to STZ injection, partially
avoided the development of destructive insulitis. DNA-
HSP65-injected mice presented a pronounced increase in
the number of CD4/CD25+ cells in the spleen and
decreased CD8+ cellular infiltrates in the pancreas. In the
spleen and pancreas of DNA-HSP65-injected mice, levels
of IL-10 were higher and levels of TNF-α were lower than
those observed in the control groups (not injected or DNA
inoculated mice). Indeed, the protective effect of DNA-
HSP65 injection in STZ-induced diabetes seemed to be
related to both: a non specific component constituted by
the vector and a specific component represented by the
activation of regulatory T cells specific for HSP65, since
the degree of protection evoked by the vaccine was com-
paratively higher.
Materials and methods
Animals
C57BL/6 male specific pathogen-free mice, 6-8 weeks old,
were bred in the Animal Facility of the University of São
Paulo at Ribeirão Preto Medical School. The animals were
maintained on a 12-hour light/dark cycle and were given
free access to food and autoclaved water. Each experiment
was performed in triplicate. The following six groups of
mice were studied: control-injected with phosphate-buff-
ered saline (PBS); DNA-HSP65 - injected with the DNA-
HSP65 vaccine; DNAv - injected with the empty vector;
STZ - injected with STZ on 5 consecutive days; DNA-
HSP65+STZ - injected with DNA-HSP65 prior to STZ;
DNAv+STZ - injected with DNAv prior to STZ.
Plasmid purification and immunization protocol
The DNA-HSP65 vaccine was derived from the pcDNA3
plasmid (Invitrogen, Carlsbad, CA), which had been pre-
viously digested with BamHI and NotI (Gibco BRL, Gaith-
ersburg, MD) by inserting a 3.3-kb fragment
corresponding to the M. leprae Hsp65 gene and the
cytomegalovirus intron A [31]. The empty pcDNA3 plas-
mid was used as a control. Luria-Bertani liquid medium
(Gibco BRL) containing ampicillin (100 μg/ml) was used
to culture DH5α Escherichia coli, transformed either with
pcDNA3 plasmid or with the plasmid containing the
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Hsp65 gene (DNA-HSP65). Plasmids were purified using
the Concert High Purity Maxiprep System (Gibco BRL).
Plasmid concentration was determined by spectropho-
tometry at λ = 260 and at λ = 280 nm using the Gene
Quant II apparatus (Pharmacia Biotech, Cambridge, UK).
Mice were intramuscularly injected with three doses (100
μg each) of DNA-HSP65 or DNAv given at 2-week inter-
vals. Control animals were injected with PBS.
STZ-induced diabetes and analysis of glycemic levels
In order to induce diabetes, male C57BL/6 mice were
given daily intra-peritoneal injections of STZ diluted in
citrate buffer, (40 mg/kg, Sigma-Aldrich, St. Louis, MO)
for five consecutive days as described before [32]. Serum
glucose concentration in blood obtained from a tail vein,
was measured using Prestige LX Smart System Test-strips
(Home Diagnostic, Inc., Fort Lauderdale, FL) once a week,
beginning 7 days after the last STZ dose. Blood glucose
levels of 200 mg/dl (12 mmol/l) or above on two consec-
utive weeks was considered confirmation of diabetes
development. The incidence of diabetes was expressed as
the percentage of animals that presented diabetes.
Cytokine production
Splenocytes were harvested, cultured in RPMI 1640
medium (5 × 106/ml; Life Technologies, Grand Island,
NY) and stimulated in vitro with 20 μg/ml of recombinant
Hsp65 protein or concanavalin A. Cytokine levels in cul-
ture supernatants were evaluated 48 hours later by ELISA
according to manufacturer instructions. Monoclonal anti-
bodies derived from the clones G281-2626 and MP6-XT3
were used as capture and biotinylated antibodies, respec-
tively, for TNF-α quantification, whereas mAb clones
JES5-2A5 and SXC-1 were used to detect IL-10. The detec-
tion limit was 15 pg/ml. Antibodies and recombinant
cytokines were purchased from Pharmingen (San Diego,
CA).
Analysis of splenic cell populations by flow cytometry
T-cell subsets were determined with mAbs specific for cell
surface markers. Phycoerythrin (PE)- labeled mAbs
included anti-CD8 mAbs (clone 53-6.7, rat IgG2a) and
anti-CD25 mAbs (PC61, rat IgG1). Fluorescein isothiocy-
anate (FITC)-labeled mAbs were also used: anti-CD4
(clone H129.19); anti-CD103 (M290, rat IgG2a); and
anti-CTLA-4 (clone 1B8, hamster IgG). In addition, a
Percp-labeled, anti-CD4 mAb (clone RM4-5) was used.
Hamster IgG and rat IgG2a, together with rat IgG2b
labeled with PE, FITC or Percp, were used as isotype con-
trols. All mAbs were purchased from PharMingen and
were used according to manufacturer instructions.
Spleen cells (1 × 107/ml) were initially incubated for 30
min at 4°C with Fc Block (1 μg/106 cells; PharMingen).
The cells were then incubated with the proper mAb (0.75
μg/106 cells) for 30 minutes at 4°C in total darkness. Lym-
phocytes were analyzed through flow cytometry using the
CellQuest computer program (FACSort; Becton Dickin-
son, San Jose, CA). Ten thousand events per sample were
collected, and double-color fluorescence-activated cell
sorter analysis was performed as described elsewhere [33].
Histology and immunohistochemistry
Five weeks after the final STZ injection, the pancreas were
removed and sections (4-5 μm) were stained with hema-
toxylin-eosin (Merck, Whitehouse Station, NJ). The
degree of insulitis was scored using the following scale: 0
= intact islet; 1 = peri-insulitis; 2 = moderate insulitis (<
50% of the islet infiltrated); 3 = severe insulitis (≥ 50% of
the islet infiltrated); and 4 = destructive insulitis. At least
20 islets per pancreas were analyzed by two independent
examiners. Staining for CD4, CD8, IL-10 and TNF-α was
performed on cryostat acetone-fixed pancreatic sections
by incubation for 1 hour with either rat anti-mouse pri-
mary mAb (Pharmingen) diluted 1:200 in 3% bovine
serum albumin (BSA)-PBS, or with rat anti-mouse CD25
biotinylated mAb (Pharmingen) diluted 1:200 in 3%
BSA-PBS. This was followed by 1 hour of incubation with
biotin-conjugated rabbit anti-rat antibody (Pharmingen).
The color was revealed using the 3,3'-diaminobenzidine
revelation system (Vector kit; Vector Laboratory, Burlin-
game, CA). For the control of nonspecific staining, pan-
creas sections were treated without anti-mouse primary
mAb. In addition, the pancreas immunohistochemistry
was further quantified by using the image processing pro-
gram (ImageJ, U.S. National Institutes of Health,
Bethesda, Maryland, USA) [34].
Statistical Analysis
The results are presented as mean ± SD. Statistical signifi-
cance of diabetes incidence and degree of insulitis was
determined by using Fisher's exact test. For ELISA and flu-
orescence-activated cell sorter results, the statistical signif-
icance was determined by One-Way analysis of variance
followed by Tukey's test. Values of P < 0.05 were consid-
ered significant.
Results
DNA-HSP65 decreases pancreatic insulitis in STZ induced 
diabetes
Glucose concentrations were analyzed weekly after the
final STZ injection. As shown in Fig. 1A-C, administration
of DNA-HSP65 or DNAv did not induce diabetes or signif-
icantly altered diabetes incidence induced by STZ in mice.
Notably, administration of DNA-HSP65 clearly delayed
diabetes development (DNA-HSP65+STZ group) during
the first week (Fig. 1A and 1B). Diabetes incidence at this
period was 25% in DNA-HSP65+STZ group, compared
with 75% in the STZ group (Fig. 1A and 1B). However,
four weeks later, diabetes incidence was similar in the
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Effect of DNA-HSP65 on diabetes incidence and insulitis severityFigure 1
Effect of DNA-HSP65 on diabetes incidence and insulitis severity. (A) Diabetes incidence of male mice (6-8 weeks 
old) that were i.m. injected with three 100-μg doses of DNA-HSP65 or DNAv, given at 15-day intervals, after which they were 
i.p. injected or not with STZ. Control group mice received i.m. injections of PBS. (B and C) Serum glucose levels were assayed 
weekly after 5 doses of STZ administration. Additional control groups received only DNA-HSP65 or DNAv. (D) Pancreata of 
C57BL/6 mice were removed for histological analysis. Each group consisted of 10 mice. To quantify islet infiltration, at least 20 
islets from three sections per pancreas were examined in a blinded fashion. Statistical significance was determined by ANOVA 
followed by Tukey's test. *p < 0.05 and ***p < 0.001 versus control group; #p < 0.05 versus STZ groups.
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three groups that received STZ (Fig. 1A and 1C). The his-
tological pancreas analysis documented in Fig. 1D, clearly
demonstrates that previous DNA-HSP65 vaccination
determined a protective effect. As expected, mice from the
STZ group presented a clear pattern of insulitis, character-
ized by peri-insulitis (in 25% of the islets), moderate insu-
litis (in 19%), invasive insulitis (in 3.3%) and destructive
insulitis (in 2.7%). A very similar islet damage profile was
observed in the DNAv+STZ group. However, DNA-
HSP65+STZ group presented considerably less islet injury,
characterized by a significantly higher percentage of intact
islets, i.e. 81% in comparison to 50% in the STZ group
and 56% in DNAv+STZ group. Also, no destructive insuli-
tis was observed in this previously vaccinated group.
IL-10 but not TNF-α is modulated by DNA inoculation
To understand the prophylactic effect of DNA-HSP65 in
the STZ model, we initially analyzed the production of
TNF-α and IL-10 in spleen cell cultures. TNF-α levels were
higher in STZ, DNAv+STZ and DNA-HSP65+STZ derived
splenic cultures stimulated with recombinant Hsp65 or
concanavalin A than in non-stimulated cultures, however,
there was no significant difference among these three
groups (Fig. 2A). Nevertheless, in the cultures from mice
injected with DNA (vector and vaccine) before STZ diabe-
tes triggering, the stimulation with rhsp65 determined a
very significant increase in IL-10 production. Interest-
ingly, production of IL-10 was significantly higher in vac-
cinated mice in comparison to the control vector injected
group (Fig. 2B).
DNA-HSP65 activates spleen cells with a regulatory 
phenotype
The higher IL-10 production in mice that received DNA
before STZ suggested the possible contribution of regula-
tory T cells in this protection against insulitis. In this con-
text, we initially characterized the populations and
phenotypes of T cells in the spleen. Clear differences were
observed in the amounts of CD4+ and CD8+ T cells (Fig.
3). Animals that were immunized with DNA-HSP65 pre-
sented higher numbers of CD4+ cells but not of CD8+
cells. This alteration was not seen in animals injected with
the empty vector. Injection of STZ alone clearly increased
the number of both cell types and interestingly prior
administration of DNA-HSP65 or DNAv was associated
with significantly lower numbers of these cells (Figs. 3A
and 3B). The analysis of phenotypic markers indicative of
regulatory ability, including CD4+CD25highCD103+ and
CD4+CD25highCTLA-4+, clearly showed that these cells
were induced or activated in mice injected with the DNA-
HSP65 but not with the empty vector (Figs. 3C and 3D).
Moreover, DNA-HSP65 injection followed by STZ clearly
increased the number of cells showing the regulatory phe-
notypic markers in comparison to STZ group. No such up-
regulation was observed in the group of mice that received
the DNAv before induction of diabetes with STZ. Interest-
ingly, in the spleens of STZ-injected mice, high numbers
of CD4+CD25high cells were observed (data not shown),
although the numbers of CD4+CD25highCD103+ and
CD4+CD25highCTLA-4+ cells remained at similar levels as
the control group (Figs. 3C and 3D).
Pancreatic islets show decreased CD8+ cell infiltration in 
DNA-HSP65-vaccinated mice
We next considered the possibility that regulatory cells
were migrating to the pancreas to block insulitis. In the
STZ group there was pronounced pancreatic infiltration
by CD8+ cells (Fig. 4D) but not by CD4+ cells (Fig. 4C). By
evaluating the stained area for CD8+ and CD4+ cells we
observed that CD8+ cell staining was 2 fold higher than
CD4+ cell in STZ group (2,45% and 1,20% of stained area
for CD8 and CD4, respectively). In DNA-HSP65+STZ and
DNAv+STZ groups of mice, this profile was dramatically
changed showing a marked infiltration by CD4+ cells
(Figs. 4E and 4G, respectively) associated with a quite dis-
crete infiltration by CD8+ cells (Figs. 4F and 4H, respec-
tively). These groups presented CD4+ cell staining three
fold higher than CD8+ cell staining (2,40% and 0,79% for
CD4 and CD8, respectively, in DNA-HSP65+STZ group
and, 2,21% and 0,71% for CD4 and CD8, respectively, in
DNAv+STZ group).
Pancreatic islets fromDNA-HSP65 injected mice show 
increased IL-10 production
Since a higher number of CD4+ cells and a lower number
of CD8+ cells were present in the islets of DNA-HSP65-
injected and DNAv-injected mice in relation to STZ group,
we supposed that CD4+ cells with a regulatory phenotype
could be involved in down modulation of diabetes devel-
opment. To confirm the hypothesis that an anti-inflam-
matory and regulatory cytokine was involved in
protection against insulitis in this model, we investigated
the local production of IL-10 and TNF-α. In the pancreatic
islets of STZ-injected mice there was abundant local TNF-
α production and no IL-10 production (Figs. 5C and 5D,
respectively). Analysis of stained area showed that 1,25%
of total area was staining for TNF-α. The DNA-
HSP65+STZ and DNAv+STZ groups also showed local
TNF-α production. Labeled areas were 0,31% and 0,56%
for vaccinated and vector injected groups, respectively
(figs. 5E and 5G). However, DNA-HSP65+STZ and
DNAv+STZ groups of mice presented a marked IL-10 pro-
duction in the islets. The IL-10 stained area in DNA-
HSP65+STZ and DNAv+STZ was 1,52% and 1,36%,
respectively. This represented an increase of 5 and 2,5-
folds, respectively, when compared with TNF-α labeled
area (Figs. 5F and 5H).
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Cytokine production in STZ injected mice previously vaccinated with DNA-HSP65Figure 2
Cytokine production in STZ injected mice previously vaccinated with DNA-HSP65. TNF-α (A) and IL-10 (B) were 
assessed by ELISA in spleen cell cultures stimulated with recombinant Hsp65 and concanavalin A. Statistical significance was 
determined by ANOVA followed by Tukey's test. *p < 0.05 versus control group and #p < 0.05 versus STZ group.
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Assessment of spleen cell phenotype in STZ injected mice after administration of DNA-HSP65Figure 3
Assessment of spleen cell phenotype in STZ injected mice after administration of DNA-HSP65. Five weeks after 
the STZ injections, 5 × 106 spleen cells were labeled with anti-CD4, anti-CD8, anti-CD25, anti-CD103 and anti-CTLA-4 mAbs 
for fluorescence-activated cell sorter analysis. The results were expressed in total number of cells per spleen for CD4+ (A), 
CD8+ (B) T cells and CD4+CD25+CD103+ (C) and CD4+CD25+CTLA-4+ (D) T regulatory cells. Statistical significance was 
determined by ANOVA followed by Tukey's test. *p < 0.05 versus control group; #p < 0.05 versus STZ groups.
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Influx of CD4+ and CD8+ cells into the pancreatic islets of STZ-injected mice previously immunized with DNA-HSP65Figure 4
Influx of CD4+ and CD8+ cells into the pancreatic islets of STZ-injected mice previously immunized with DNA-
HSP65. After three 100-μg doses of DNA-HSP65 or DNAv, given at 15-day intervals, mice were injected with STZ. Control 
group mice received STZ only (i.p. injections). Pancreatic islets were analyzed 5 weeks after the last STZ injection. Immunos-
taining for CD4 (A, C, E and G) and CD8 receptors (B, D, F and H). Unspecific staining control (A and B). STZ group mice (C 
and D), DNA-HSP65+STZ group mice (E and F) and DNAv+STZ group mice (G and H). Quantitative analyses were performed 
by image processing program (ImageJ). Original magnification, ×20.
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TNF-α and IL-10 cytokine production in the pancreatic islets of DNA-HSP65+STZ and DNAv+STZ group miceFigure 5
TNF-α and IL-10 cytokine production in the pancreatic islets of DNA-HSP65+STZ and DNAv+STZ group 
mice. After three 100-μg doses of DNA-HSP65 or DNAv, given at 15-day intervals, they were inoculated with STZ. Control 
group mice received STZ only (i.p. injections). Pancreatic islets were analyzed from 5 weeks after the last STZ injection. 
Unspecific staining control (A and B). Levels of TNF-α (A, C, E and G) and IL-10 (B, D, F and H) were evaluated in STZ group 
mice (C and D), DNA-HSP65+STZ group mice (E and F) and DNAv+STZ group mice (G and H). Quantitative analyses were 
performed by image processing program (ImageJ). Original magnification, ×20.
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Discussion
The present study clearly demonstrated that previous vac-
cination with DNA-HSP65 did not aggravate or accelerate
diabetes development induced by STZ. In addition, this
genetic construction triggered a beneficial effect character-
ized by a delay in diabetes incidence, a higher percentage
of intact islets and also absence of destructive insulitis.
The last two effects were also determined by the empty
vector, even though they were much less accentuated.
This protective effect was clearly associated with an immu-
nomodulatory activity over cytokines and T cell subsets in
both, spleen and islets of Langerhans. TNF-α levels
induced in vitro by rhsp65 or ConA were similarly high in
STZ, DNA-HSP65+STZ and DNAv+STZ groups. However,
the local production of TNF-α in the islets was clearly
down modulated by both, DNAv and DNA-HSP65. Mice
groups injected with DNAv and DNA-HSP65 before STZ
also produced significantly higher IL-10 levels in compar-
ison to STZ group. It was also striking the finding that IL-
10 levels were significantly more elevated in the DNA-
HSP65 group than in the corresponding DNAv+STZ con-
trol. This IL-10 profile in the periphery (spleen) was coin-
cident with a corresponding pattern at the pancreas, i.e.,
IL-10 absence in STZ group and clear IL-10 production in
DNA injected mice. These findings are consistent with the
widely accepted role of IL-10 as a suppressive cytokine
involved in autoimmunity control. For example, Zhang et
al., showed that systemic administration of IL-10 plasmid
DNA alleviated insulitis and reduced disease incidence in
experimental autoimmune diabetes [35]. Moreover, oral
or nasal mucosal immunization with Mycobacterium
Hsp65 that resulted in protection against atherosclerosis
was also related to IL-10 production [36]. Although IL-10
production was stimulated by both, DNA-HSP65 and
DNAv, it is important to emphasize that only animals
immunized with DNA-HSP65 presented an increased
number of CD4+CD25highCD103+ cells. Zanin-Zhorov et
al., reported that the human 60-kDa heat shock protein
(Hsp60) acts as a co-stimulator of human regulatory T
cells (Treg), both CD4+CD25intermediate and
CD4+CD25high, via innate TLR2 signaling. They observed
that the treatment of Treg with Hsp60 or its peptide p277
before anti-CD3 activation significantly enhanced the
ability of relatively low concentrations of Treg cells to
down-regulate CD4+CD25- or CD8+ target T cells,
detected as inhibition of target T cell proliferation and
IFN-γ and TNF-α secretion. Interestingly these Hsp60-
treated Treg cells suppressed target T lymphocytes by
both, cell-to-cell contact and secretion of TGF-β and IL-10
[37]. It is possible therefore that DNA-HSP65 immuniza-
tion is also priming Hsp65 antigen-specific B and/or T
lymphocytes, including Treg cells. These data reinforce
our finding that a specific immune response also played a
significant role in the protection against diabetes since
administration of DNA-HSP65 was associated with higher
percentage of intact islets than DNAv, despite IL-10 elici-
tation by both DNA preparations.
The relevance of the regulatory role of CD4+CD25+ T cells
has been described in different kinds of experimental dia-
betes models. In a CD8+ T cell-mediated model of type 1
diabetes, Green et al., showed that CD4+CD25+ T cells
avoided pancreatic β cell destruction [38] by preventing
intra-islet differentiation of CD8+ T cells into cytotoxic T
lymphocyte effectors [38]. Intranasal administration of
islet auto-antigens in mice also elicited antigen-specific
CD4+CD25+ Treg cells able to prevent development of
type 1 diabetes [39]. In agreement with these findings, our
results show that a higher number of spleen cells with this
regulatory phenotype was present in DNA-HSP65-
injected mice. Interestingly, the number of
CD4+CD25highCD103+ and CD4+CD25highCTLA-4+ cells
in the spleen of the DNA-HSP65-injected mice was signif-
icantly higher than in those injected only with STZ. In
addition, CD8+ cell infiltration was reduced and levels of
IL-10 were higher in the pancreatic islets of DNAv-injected
mice, suggesting that DNA-HSP65 injection activated a
regulatory mechanism, characterized by IL-10 production
that inhibited the infiltration of inflammatory cells into
the pancreas. This regulatory ability of DNA-HSP65 and
its association with higher IL-10 production was already
described by our group in experimental arthritis and also
in NOD mice [29,30,40]. Together these findings are
highly supported by the well accepted immunoregulatory
ability of microbial hsps [41]. In this context it is tempting
to suggest that HSP65 is, at least partially, responsible for
the islet recovery and reversal of murine type 1 diabetes
observed in NOD mice after Complete Freund's Adjuvant
administration [42,43].
An interesting and useful challenge for the future is to
unravel the exact immunological scenario that will favor
maximal protection against tuberculosis or against
autoimmunity.
Conclusion
In conclusion, the data presented in this study encourage
us to invest in the regulatory potential of the DNA-HSP65
construct. Our findings have important implications for
the development of new immune therapy strategies to
combat autoimmune diseases.
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